arirang mobile

Cuba administers home-produced Covid-19 vaccines to children as young as two, while U.S. has doubts over administering Pfizer booster shots to young adults
Updated: 2021-09-18 12:12:23 KST

A 2-year-old child sits atop her mother's lap while she's getting her first Covid-19 jab.

"I was very doubtful and worried at the beginning, but then I got informed through social networks and television, and they really give guarantees that Soberana 02 is effective for children."

Cuba this Thursday became the first country to inoculate Covid-19 doses to children as young as two, by launching a massive vaccine roll out for ages two to 10 with their home-produced vaccines.

"In Cuba, we have seen an increase in cases in pediatric ages. That is the reason why our scientific community first decided to take the vaccines to a clinical trial, both Soberana and Abdala. Then, it was decided as a country to approve it in pediatric ages."

Meanwhile, the U.S. sits at the other end of the spectrum, with vaccine experts discouraging administering Pfizer booster shots to young adults and teens over safety concerns.
The majority of the U.S. FDA's Vaccines and Related Biological Products Advisory Committee on Friday voted against a nationwide booster shot campaign for all ages, especially when not enough data has been compiled to guarantee the shots' efficacy and safety.
For the booster campaign due to start next week, experts advised to dole out shots to only high-risk groups first those 65 and over and healthcare workers.

"I think we need the scientific evidence before we go forward with such a large and important campaign such as boosting And I really think within six months we'll have very clear answers about this issue."

Also, on Friday, the U.S. Centers for Disease Control and Prevention, or CDC, found that Moderna's Covid-19 vaccines are more effective in preventing hospitalization than those from its competitors.
After collecting data from nearly 37-hundred people, the CDC saw that Moderna vaccines were 93 percent effective, while Pfizer showed 88 percent and Johnson & Johnson showed 71 percent efficacy.
Kim Yeon-seung, Arirang News
Reporter :